En V Veno Medical Corp NVNO
We take great care to ensure that the data presented and summarized in this overview for enVVeno Medical Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVNO
View all-
Kingdon Capital Management, L.L.C. New York, NY654KShares$3.28 Million0.43% of portfolio
-
Perceptive Advisors LLC New York, NY623KShares$3.12 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA574KShares$2.88 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT496KShares$2.48 Million0.17% of portfolio
-
Act Capital Management, LLC Wayne, PA401KShares$2.01 Million3.48% of portfolio
-
Ubs Oconnor LLC Chicago, IL226KShares$1.13 Million0.08% of portfolio
-
Adar1 Capital Management, LLC Austin, TX202KShares$1.01 Million0.25% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA172KShares$862,8971.05% of portfolio
-
Geode Capital Management, LLC Boston, MA137KShares$688,6540.0% of portfolio
-
Morgan Stanley New York, NY97.6KShares$488,7250.0% of portfolio
Latest Institutional Activity in NVNO
Top Purchases
Top Sells
About NVNO
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Insider Transactions at NVNO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2024
|
Hamed Alavi Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
8,334
-100.0%
|
$50,004
$6.22 P/Share
|
|
Mar 13
2024
|
Hamed Alavi Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,334
+50.0%
|
$25,002
$3.59 P/Share
|
|
Sep 13
2022
|
Matthew Jenusaitis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,041
+13.07%
|
-
|
|
Sep 13
2022
|
Robert Gray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,041
+11.97%
|
-
|
|
Aug 16
2022
|
Francis Duhay Director |
BUY
Open market or private purchase
|
Direct |
7,751
+27.04%
|
$46,506
$6.14 P/Share
|
|
Jun 30
2022
|
Sanjay Shrivastava Director |
BUY
Open market or private purchase
|
Direct |
1,000
+20.46%
|
$3,000
$3.85 P/Share
|
|
Jun 27
2022
|
Robert Andrew Berman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.18%
|
$7,500
$3.8 P/Share
|
|
Nov 30
2021
|
Craig Glynn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Nov 30
2021
|
Marc H. Glickman SVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+49.6%
|
-
|
|
Nov 30
2021
|
Robert Andrew Berman Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+49.05%
|
-
|
|
Nov 19
2021
|
Robert Andrew Berman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+20.54%
|
$14,000
$7.43 P/Share
|
|
Nov 16
2021
|
Robert Andrew Berman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+25.85%
|
$14,000
$7.87 P/Share
|
|
Nov 16
2021
|
Sanjay Shrivastava Director |
BUY
Exercise of conversion of derivative security
|
Direct |
388
+11.84%
|
-
|
|
Sep 13
2021
|
Robert Gray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,042
+13.61%
|
-
|
|
Sep 13
2021
|
Matthew Jenusaitis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,042
+15.04%
|
-
|
|
Aug 25
2021
|
Matthew Jenusaitis Director |
BUY
Open market or private purchase
|
Direct |
1,300
+21.17%
|
$9,100
$7.7 P/Share
|
|
Jun 16
2021
|
Robert Gray Director |
BUY
Open market or private purchase
|
Direct |
2,000
+26.41%
|
$12,000
$6.25 P/Share
|
|
May 21
2021
|
Marc H. Glickman SVP & Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,600
+50.0%
|
$8,000
$5.9 P/Share
|
|
May 18
2021
|
Robert Andrew Berman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+44.54%
|
$15,000
$5.47 P/Share
|
|
May 17
2021
|
Francis Duhay Director |
BUY
Open market or private purchase
|
Direct |
9,492
+41.9%
|
$47,460
$5.33 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 8.33K shares |
|---|
| Open market or private sale | 8.33K shares |
|---|